Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Authors
Keywords
-
Journal
Translational Neurodegeneration
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-03-18
DOI
10.1186/s40035-022-00292-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The complexity of Alzheimer's disease: an evolving puzzle
- (2021) Sandro Sorbi et al. PHYSIOLOGICAL REVIEWS
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tau immunotherapy is associated with glial responses in FTLD-tau
- (2021) Boram Kim et al. ACTA NEUROPATHOLOGICA
- Evaluation of Aducanumab for Alzheimer Disease
- (2021) G. Caleb Alexander et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease
- (2021) Gai Ayalon et al. Science Translational Medicine
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- Development of immunoprecipitation – two-dimensional liquid chromatography – mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients
- (2021) Sebastiaan Bijttebier et al. JOURNAL OF CHROMATOGRAPHY A
- Microglial activation and tau propagate jointly across Braak stages
- (2021) Tharick A. Pascoal et al. NATURE MEDICINE
- Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
- (2021) Tien Dam et al. NATURE MEDICINE
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
- (2021) Stephen Salloway et al. NATURE MEDICINE
- Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer’s disease
- (2021) Preeti Bakrania et al. MOLECULAR PSYCHIATRY
- Sodium Oligomannate: First Approval
- (2020) Yahiya Y. Syed DRUGS
- Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease
- (2020) David Gate et al. NATURE
- Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau
- (2020) Nadine Ait-Bouziad et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model
- (2020) Shoutang Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease
- (2020) Joseph W. Lewcock et al. NEURON
- Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating
- (2020) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Amyloid-β Immunotherapy for Alzheimer's Disease - Is It Now A Long Shot…?
- (2019) Francesco Panza et al. ANNALS OF NEUROLOGY
- Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody
- (2019) Marie Albert et al. BRAIN
- Alzheimer disease and aducanumab: adjusting our approach
- (2019) Dennis J. Selkoe Nature Reviews Neurology
- Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
- (2019) Lisa Vermunt et al. Alzheimers & Dementia
- Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression
- (2019) Xinyi Wang et al. CELL RESEARCH
- Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease
- (2019) Michael Ewers et al. Science Translational Medicine
- Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
- (2019) Justin M. Long et al. CELL
- Diagnosis and Management of Dementia: Review
- (2019) Zoe Arvanitakis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Advances and considerations in AD tau-targeted immunotherapy
- (2019) Alice Bittar et al. NEUROBIOLOGY OF DISEASE
- Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
- (2019) Gregory Klein et al. Alzheimers Research & Therapy
- Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
- (2018) Christopher H. van Dyck BIOLOGICAL PSYCHIATRY
- Gut Microbiota is Altered in Patients with Alzheimer’s Disease
- (2018) Zhen-Qian Zhuang et al. JOURNAL OF ALZHEIMERS DISEASE
- Tau-targeting therapies for Alzheimer disease
- (2018) Erin E. Congdon et al. Nature Reviews Neurology
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
- (2018) Joseph W. Arndt et al. Scientific Reports
- Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
- (2018) Bernd Bohrmann et al. JOURNAL OF ALZHEIMERS DISEASE
- FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease
- (2018) Petr Novak et al. Alzheimers Research & Therapy
- Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly
- (2017) Annamaria Cattaneo et al. NEUROBIOLOGY OF AGING
- Early and Late CNS Inflammation in Alzheimer’s Disease: Two Extremes of a Continuum?
- (2017) A. Claudio Cuello TRENDS IN PHARMACOLOGICAL SCIENCES
- Gut microbiome alterations in Alzheimer’s disease
- (2017) Nicholas M. Vogt et al. Scientific Reports
- The amyloid hypothesis of Alzheimer's disease at 25 years
- (2016) Dennis J Selkoe et al. EMBO Molecular Medicine
- Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy
- (2016) Francesco Panza et al. Immunotherapy
- CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
- (2016) Bob Olsson et al. LANCET NEUROLOGY
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- How neuroinflammation contributes to neurodegeneration
- (2016) R. M. Ransohoff SCIENCE
- Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease
- (2016) Myles R. Minter et al. Scientific Reports
- A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease
- (2015) Michael G. Agadjanyan et al. Alzheimers & Dementia
- TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
- (2015) Yaming Wang et al. CELL
- Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
- (2015) Elizabeth Head et al. Current Alzheimer Research
- Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
- (2015) J. Butchart et al. NEUROLOGY
- Primary age-related tauopathy (PART): a common pathology associated with human aging
- (2014) John F. Crary et al. ACTA NEUROPATHOLOGICA
- Amyloid and tau in the brain in sporadic Alzheimer’s disease: defining the chicken and the egg
- (2014) Cheryl A. Hawkes et al. ACTA NEUROPATHOLOGICA
- Toll-Like Receptors in Alzheimer’s Disease: A Therapeutic Perspective
- (2014) Maria Gambuzza et al. CNS & Neurological Disorders-Drug Targets
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
- (2014) Eva Kontsekova et al. Alzheimers Research & Therapy
- Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease
- (2014) Adam C. Naj et al. JAMA Neurology
- Immunotherapy in Alzheimer’s Disease: Do We Have All the Pieces of the Puzzle?
- (2013) Marie Sarazin et al. BIOLOGICAL PSYCHIATRY
- Immunotherapy for Alzheimer’s disease: hoops and hurdles
- (2013) Cynthia A Lemere Molecular Neurodegeneration
- Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
- (2013) D. M. Holtzman et al. Cold Spring Harbor Perspectives in Medicine
- An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A
- (2012) O. Adolfsson et al. JOURNAL OF NEUROSCIENCE
- Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
- (2012) Bengt Winblad et al. LANCET NEUROLOGY
- The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
- (2012) Iryna Benilova et al. NATURE NEUROSCIENCE
- Immunotherapy for Alzheimer disease—the challenge of adverse effects
- (2012) Yu-Hui Liu et al. Nature Reviews Neurology
- Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid- Immunotherapy
- (2011) A. Wang et al. JOURNAL OF NEUROSCIENCE
- Alzheimer's disease
- (2011) Clive Ballard et al. LANCET
- Biomarkers in frontotemporal lobar degenerations—Progress and challenges
- (2011) William T. Hu et al. PROGRESS IN NEUROBIOLOGY
- Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease
- (2010) Erik Portelius et al. ACTA NEUROPATHOLOGICA
- Immunotherapy for Alzheimer’s disease
- (2010) D. Morgan JOURNAL OF INTERNAL MEDICINE
- Alzheimer's disease: clinical trials and drug development
- (2010) Francesca Mangialasche et al. LANCET NEUROLOGY
- Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
- (2009) Bruno Vellas et al. Current Alzheimer Research
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
- (2009) Clifford R Jack et al. LANCET NEUROLOGY
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
- (2008) Clive Holmes et al. LANCET
- Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests
- (2008) K A Bates et al. MOLECULAR PSYCHIATRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now